Papers/PMID:39248210
The effects and safety of testosterone replacement therapy for men with hypogonadism: the TestES evidence synthesis and economic evaluation.
Health technology assessment (Winchester, England)2024The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
testosterone — no detected effect on incidence of cardiovascular disease (composite)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result“There was no difference between the testosterone replacement therapy group (120/1601, 7.5%) and placebo group (110/1519, 7.2%) in the incidence of cardiovascular and/or cerebrovascular events (13 studies, odds ratio 1.07, 95% confidence interval 0.81 to 1.42; p = 0.62).”
Quoted verbatim from The effects and safety of testosterone replacement therapy for men with hypogonadism: the TestES evidence synthesis and economic evaluation.. - Study
- meta-analysis
- Population
- Men with male hypogonadism; individual participant data and aggregate meta-analysis of placebo-controlled randomised trials of any testosterone replacement formulation (13 studies for this endpoint)
Effect 1.07 odds ratio, 95% CI 0.81 to 1.42
The effects and safety of testosterone replacement therapy for men with hypogonadism: the TestES evidence synthesis and economic evaluation.2024PMID:39248210Permalink